Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
26.58
+2.68 (11.21%)
At close: Aug 13, 2025, 4:00 PM
26.68
+0.10 (0.38%)
After-hours: Aug 13, 2025, 6:19 PM EDT
Apellis Pharmaceuticals Revenue
Apellis Pharmaceuticals had revenue of $178.49M in the quarter ending June 30, 2025, a decrease of -10.61%. This brings the company's revenue in the last twelve months to $754.65M, up 20.02% year-over-year. In the year 2024, Apellis Pharmaceuticals had annual revenue of $781.37M with 97.02% growth.
Revenue (ttm)
$754.65M
Revenue Growth
+20.02%
P/S Ratio
3.96
Revenue / Employee
$1,062,886
Employees
710
Market Cap
3.36B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 781.37M | 384.78M | 97.02% |
Dec 31, 2023 | 396.59M | 321.17M | 425.83% |
Dec 31, 2022 | 75.42M | 8.86M | 13.31% |
Dec 31, 2021 | 66.56M | -184.08M | -73.44% |
Dec 31, 2020 | 250.65M | - | - |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
APLS News
- 11 days ago - Apellis Pharmaceuticals, Inc. (APLS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Apellis Pharmaceuticals: The Picture Becomes Clearer - Seeking Alpha
- 13 days ago - Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 15 days ago - FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio - Benzinga
- 15 days ago - FDA Approves Apellis' EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older - GlobeNewsWire
- 20 days ago - Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting - GlobeNewsWire
- 6 weeks ago - Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan) - PRNewsWire